Glide, which was established in 2001, has developed a solid dose delivery system for a range of drug and vaccine applications. The company aims to offer an alternative to the traditional needle injection currently used in many forms of vaccination. The device is operated by a spring mechanism which pushes solid drugs through the skin and into the underlying tissue, where they dissolve and are released into the patient’s bloodstream. Drugs in a solid dose form also make them more stable, removing the need for refrigeration and offering the potential to generate substantial cost savings. Oxford Technology 4 VCT, Oxford Capital Partners and a number of business angels previously provided the company with a £2.3m third round of funding in 2007. “This funding reflects the major progress we have made in positioning the Glide SDI system as a mainstream alternative for the injection of small molecules, biopharmaceuticals and vaccines,” says Glide Pharma founder Charles Potter. Picture source
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.